D. E. Shaw & Co., Inc. Galectin Therapeutics Inc Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $53,372 - $85,519	-20,607 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.07 - $5.1 $52,097 - $128,356	-25,168 Reduced 54.98%	20,607 $66,000
Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $10,876 - $14,260	-5,549 Reduced 10.81%	45,775 $99,000
Q4 2020 Feb 16, 2021	BUY	$2.24 - $2.87 $114,965 - $147,299	51,324 New	51,324 $115,000
Q3 2020 Nov 16, 2020	SELL	$2.53 - $3.64 $199,422 - $286,915	-78,823 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $130,846 - $248,292	78,823 New	78,823 $241,000
Q1 2020 May 15, 2020	SELL	$1.51 - $3.0 $28,828 - $57,276	-19,092 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.79 - $4.32 $17,200 - $26,632	6,165 Added 47.69%	19,092 $55,000
Q3 2019 Nov 14, 2019	SELL	$3.0 - $4.05 $19,713 - $26,612	-6,571 Reduced 33.7%	12,927 $47,000
Q2 2019 Aug 14, 2019	BUY	$3.61 - $5.0 $11,364 - $15,740	3,148 Added 19.25%	19,498 $81,000
Q1 2019 May 15, 2019	BUY	$3.86 - $6.02 $63,111 - $98,427	16,350 New	16,350 $84,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.